Sellas Life Sciences Group
7 clinical trials · Sponsor
◉ Watch Sellas Life Sciences Group
| Record | Firm | Date |
|---|---|---|
| Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML (NCT04588922) | Sellas Life Sciences Group | 2021-05-10 |
| Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 (NCT04229979) | Sellas Life Sciences Group | 2021-02-08 |
Track Sellas Life Sciences Group automatically
Every clearance here is in the API, with alerts when new ones post.